Valuation
- Market cap
- 12,559,000
- Revenue TTM
- $1,230,000
- Net income TTM
- $-12,150,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -987.80%
- Debt to equity
- 0.00
Trading
- Volume
- 343,300
- Avg volume
- 133,146
- Day's range
- $2.40 – $2.98
- Shares out
- 4,407,000
- Stochastic %K
- 1%
- Beta
- -1.09
- Analysts
- Strong Sell
- Price target
- $10.00
Company profile
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUEL...
Show more
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 844 427 8100
- Website
- https://seastarmedical.com
- Address
- 3513 Brighton Boulevard, Suite 410, Denver, United States
Latest news
No headlines yet.
